Targeted drug delivery to specific brain regions is a critical step in the preclinical development of therapies for neurological and neurodegenerative diseases. In non-human primate (NHP) studies, many sponsors initially request traditional stereotactic brain injection based on pre-operative imaging and atlas-based coordinates. However, when the therapeutic target involves deep, small, or anatomically variable nuclei-such as the substantia nigra (SN) or other micro-nuclear structures-these conventional approaches often fail to achieve the required precision and reproducibility.
At Prisys Biotech, we strongly recommend the ClearPoint® real-time intraoperative MRI (iMRI)–guided navigation and delivery system, combined with convection-enhanced delivery (CED), to address the fundamental limitations of traditional brain targeting methods.
The Core Limitations of Conventional Stereotactic Brain Delivery
Traditional brain delivery techniques rely on static pre-operative MRI/CT images, rigid stereotactic frames, and coordinate registration. While this approach may be acceptable for large cortical or ventricular targets, it presents major risks when applied to deep brain nuclei:
- Brain shift after burr hole opening or cannula insertion
- Inter-individual anatomical variability in NHPs
- Inability to visualize the actual cannula tip position
- No real-time confirmation of drug distribution
These limitations become especially critical for small structures such as the substantia nigra, where even a 1–2 mm deviation can result in complete target miss or off-target exposure.
Why iMRI Is Essential for Accurate Brain Targeting
1. Sub-Millimetric Targeting Accuracy
The ClearPoint® system enables real-time iMRI guidance with sub-millimetric accuracy. Unlike atlas-based stereotaxy, iMRI allows continuous visualization of both the planned trajectory and the actual cannula position inside the brain.
This capability is essential for:
- Substantia nigra (SN) targeting
- Basal ganglia micro-nuclei
- Brainstem and midbrain structures
- Any target with limited anatomical tolerance
Real-time trajectory correction ensures that drug delivery reaches the intended nucleus rather than an adjacent functional region.
2. Real-Time Visualization of the Entire Delivery Process
ClearPoint transforms brain drug delivery from a "blind injection" into a fully visualized procedure:
Intraoperative monitoring:
The infusion process can be observed directly under MRI, allowing immediate adjustment of cannula depth, angle, or infusion parameters.
Immediate coverage assessment:
Post-infusion imaging reveals the actual volume of distribution (Vd) within the target region, providing objective confirmation of delivery success.
This is particularly important for dose–effect interpretation in preclinical studies.
Why iMRI Must Be Combined with CED for Small Brain Nuclei
3. Convection-Enhanced Delivery (CED): The Only Viable Option for Micro-Targets
For small nuclei such as the SN, simple needle injection is insufficient. Passive diffusion leads to:
- Limited tissue penetration
- Backflow along the needle track
- Unpredictable drug distribution
CED overcomes these challenges by using a controlled pressure gradient to actively distribute the drug through the interstitial space.
Key advantages include:
- Homogeneous distribution within small nuclei
- Predictable volume of coverage
- Reduced off-target exposure
- Direct bypass of the blood–brain barrier (BBB)
In practice, accurate SN delivery is only achievable when iMRI guidance and CED are used together.
4. Enhanced Safety and Minimally Invasive Design
The ClearPoint system employs MRI-compatible, ultra-fine cannulas (e.g., SmartFlow®), designed to minimize tissue disruption and backflow.
Benefits include:
- Lower risk of hemorrhage
- Reduced inflammation and tissue damage
- Improved procedural reproducibility
- Higher animal welfare compliance in NHP studies
High Translational Value from NHP to Human Studies
5. True Translational Continuity
One of the strongest advantages of ClearPoint® is its direct clinical translatability. The same platform, workflow, and consumables are used in:
- Human clinical trials
- Large-animal NHP studies
As a result, data generated in Prisys Biotech's NHP models offer:
- More reliable dose extrapolation
- Higher predictive value for clinical safety
- Reduced translational risk in CNS drug development
Conclusion
If traditional stereotactic brain injection is comparable to "shooting with eyes closed," then iMRI-guided CED delivery is equivalent to real-time GPS navigation with live feedback.
For deep, small, and functionally critical brain nuclei such as the substantia nigra, only the combination of iMRI and CED can ensure that the drug truly reaches the intended target-with precision, safety, and translational relevance.
At Prisys Biotech, our ClearPoint® iMRI-guided brain navigation and delivery platform provides sponsors with the confidence that every microliter of drug is delivered exactly where it matters most.
